Afamelanotide

Overview

Afamelanotide is a synthetic tridecapeptide analog of Alpha-MSH (alpha-melanocyte-stimulating hormone) developed by Clinuvel Pharmaceuticals. Marketed as Scenesse, it received FDA approval in October 2019 for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder of heme biosynthesis in which accumulation of protoporphyrin IX in the skin causes severe phototoxic reactions upon exposure to visible light.

Afamelanotide is also known by its research designation [Nle4, D-Phe7]-alpha-MSH or NDP-alpha-MSH, reflecting its two key amino acid substitutions relative to native alpha-MSH. These modifications, first described by Victor Hruby and colleagues at the University of Arizona in the 1980s, dramatically enhance receptor binding affinity, metabolic stability, and biological potency compared to the endogenous peptide.

The compound is formulated as a bioresorbable subcutaneous implant that releases afamelanotide over approximately 60 days, stimulating eumelanin production in melanocytes and providing photoprotective darkening of the skin. This melanogenesis-based approach is fundamentally distinct from topical sunscreens or physical UV barriers.

Structure and Pharmacology

Molecular characteristics:

• Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
• Length: 13 amino acids
• Molecular weight: 1,647.9 Da
• Key modifications: Norleucine (Nle) at position 4 (replacing Met), D-Phenylalanine at position 7 (replacing L-Phe), N-terminal acetylation, C-terminal amidation
• Formulation: Bioresorbable poly(D,L-lactide-co-glycolide) subcutaneous implant containing 16 mg afamelanotide

Melanocortin 1 Receptor Activation

Afamelanotide is a potent, full receptor agonist of the Melanocortin system, particularly the melanocortin 1 receptor (MC1R):

MC1R binding and signal transduction:

1. Receptor engagement: Afamelanotide binds MC1R on epidermal melanocytes with approximately 100-fold greater potency than native alpha-MSH
2. cAMP cascade: MC1R activation stimulates adenylyl cyclase via GPCR Gs-protein coupling, increasing intracellular cAMP
3. MITF activation: Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein), upregulating microphthalmia-associated transcription factor (MITF)
4. Melanogenic enzyme induction: MITF drives transcription of tyrosinase, TRP-1, and TRP-2, the rate-limiting enzymes of melanin biosynthesis
5. Eumelanin production: The melanogenic cascade preferentially synthesizes eumelanin (brown-black pigment) rather than pheomelanin (red-yellow pigment)

Photoprotective mechanism:

• Eumelanin absorbs UV and visible light photons across a broad spectrum
• Melanin granules (melanosomes) are transferred from melanocytes to surrounding keratinocytes, forming supranuclear caps that shield nuclear DNA
• Eumelanin also scavenges reactive oxygen species generated by photon absorption in skin chromophores
• In EPP patients, increased eumelanin provides a protective filter that reduces the amount of visible light reaching accumulated protoporphyrin IX in dermal blood vessels and tissues

Modifications and Stability

The two amino acid substitutions in afamelanotide are critical to its pharmacological properties:

• Nle4 (norleucine replacing methionine): Eliminates the sulfur-containing methionine side chain, preventing oxidative degradation that rapidly inactivates native alpha-MSH; norleucine is isosteric with methionine but resistant to oxidation
• D-Phe7 (D-phenylalanine replacing L-phenylalanine): The D-configuration at this position enhances receptor binding affinity and confers resistance to enzymatic degradation by proline endopeptidase and other peptidases

Together, these modifications extend the functional half-life from minutes (native alpha-MSH) to hours (afamelanotide) and increase potency approximately 100-fold. This approach to improving peptide stability through non-natural amino acid substitutions is a common strategy in peptide synthesis.

Clinical Applications

Erythropoietic Protoporphyria

EPP is caused by deficiency of ferrochelatase, the terminal enzyme in heme biosynthesis, leading to accumulation of protoporphyrin IX (PPIX) in erythrocytes, plasma, and skin. PPIX absorbs light in the visible spectrum (peak ~408 nm, Soret band), generating singlet oxygen and free radicals that cause intense burning pain, erythema, and edema upon light exposure. Patients with EPP are often unable to tolerate even brief outdoor activities.

In the Phase III trials, afamelanotide implants administered every 60 days increased the duration of direct sunlight exposure without pain compared to placebo implants. Patients reported improved quality of life and increased ability to participate in outdoor activities.

Dosing:

• 16 mg subcutaneous implant administered by a healthcare professional every 60 days
• Implanted above the anterior supra-iliac crest
• Treatment is seasonal in some patients, corresponding to periods of greatest light exposure
• Available only through a restricted program (SCENESSE REMS) due to the need for healthcare professional administration

Investigated Applications

• Vitiligo: Repigmentation of depigmented skin patches when combined with narrowband UVB phototherapy
• Solar urticaria: Photoprotection in light-triggered urticaria
• Polymorphous light eruption: Prevention of sun-induced skin eruptions
• Photoprotection in organ transplant recipients: Reduction of UV-induced skin damage in immunosuppressed patients at high skin cancer risk
• Hailey-Hailey disease: Investigated based on melanocortin anti-inflammatory effects

Pharmacokinetics

Following subcutaneous implant insertion:

• Tmax: 1-2 days (initial peak)
• Release duration: Approximately 60 days (sustained release from biodegradable matrix)
• Half-life: ~15 hours (terminal elimination of released peptide)
• Metabolism: Proteolytic peptide degradation; no hepatic CYP450 involvement
• Melanogenic response: Skin darkening begins within days and peaks at approximately 2-4 weeks

Safety Profile

• Implant site reactions: Discoloration, pain, erythema, and minor procedural discomfort at the insertion site
• Skin hyperpigmentation: Expected pharmacological effect; nevi (moles) may darken and should be monitored dermatoscopically
• Nausea: 12-17%
• Headache: 10-20%
• Fatigue: Mild, transient
• Oropharyngeal pain and cough: Reported in some patients

Long-term melanocyte stimulation raises theoretical concerns regarding melanocytic neoplasia. Clinical trial surveillance data and post-marketing studies have not identified an increased melanoma risk, but regular dermatological examinations with full-body skin checks are recommended for all patients receiving afamelanotide.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Afamelanotide (Scenesse) is available only through a restricted REMS program. Always consult a qualified healthcare professional.

Administration notes: The implant must be administered by a healthcare professional using the provided applicator. Seasonal dosing may be appropriate, corresponding to periods of greatest light exposure. Available only through the SCENESSE REMS program. Patients should undergo regular full-body dermatological examinations to monitor nevi (moles) for changes.

Relationship to Other Melanocortin Peptides

Afamelanotide shares the same NDP-MSH core pharmacophore as Melanotan II and bremelanotide (PT-141), but differs in selectivity, indication, and regulatory status. Afamelanotide is a linear tridecapeptide with preferential MC1R activity, while Melanotan II is a cyclic heptapeptide with broader melanocortin receptor activity (MC1R, MC3R, MC4R, MC5R). Setmelanotide represents another melanocortin-based therapeutic targeting MC4R for genetic obesity.

The melanocortin peptide family illustrates how structural modifications to a single endogenous peptide scaffold can yield therapeutics with distinct receptor selectivity profiles and clinical applications, advancing the broader drug development pipeline.